Convert Pharmaceuticals

Executive Summary

Convert Pharmaceuticals is a Belgian biotech company founded in 2015, specializing in hypoxia-activated prodrugs for solid tumors. Its technology exploits the hypoxic microenvironment common in many cancers (e.g., pancreatic, ovarian, breast, prostate, head and neck) to selectively release potent anticancer agents, potentially improving efficacy and reducing systemic toxicity. The company has not yet disclosed specific clinical candidates or financing details, indicating an early preclinical stage. Convert’s platform could address a significant unmet need in hard-to-treat solid tumors where hypoxia limits standard therapy effectiveness. The company is based in Leuven, Belgium, and remains private with no publicly available pipeline or milestones. Given the lack of clinical data, the near-term value hinges on advancing proprietary molecules into the clinic or securing partnerships to fund development. The competitive landscape includes other hypoxia-targeted approaches, but Convert’s prodrug design may offer differentiation if preclinical results are compelling.

Upcoming Catalysts (preview)

• Q4 2026Preclinical data release for lead candidate70% success
• H1 2027IND filing or clinical trial application50% success
• TBDStrategic partnership or licensing deal40% success